First mRNA Flu Vaccine for Adults 50+ Now Available in Billings

A new option for flu prevention has hit the shelves in Billings, Montana, as the first mRNA-based influenza vaccine becomes available for adults aged 50 and older. While the annual push for flu shots is a seasonal staple, this year's vaccines are built differently, moving away from traditional egg-based production toward the synthetic instructions used during the COVID-19 pandemic.

The vaccine, known as mFlusiva, was granted approval by the U.S. Food and Drug Administration in August 2026. For those in the 50-to-64 age bracket, the FDA provided full approval, while those 65 and older received accelerated approval pending a final study to confirm clinical benefits. This rollout marks the first time mRNA technology—which provides the body with a “recipe” to recognize viral proteins—is being deployed to combat the seasonal flu.

The efficiency gap between eggs and mRNA

For decades, the flu shot has been a race against time. Most traditional vaccines are grown in chicken eggs, a cumbersome process that can take six months or more. This timeline forces scientists to predict which strains will dominate the coming winter long before the season actually arrives. If the virus mutates in the interim, the result is a “mismatch” that lowers the vaccine’s effectiveness.

mRNA technology removes the biological bottleneck of the egg. Moderna claims that mFlusiva can move from strain selection to full production in roughly two to three months. By slashing the production window by half, health providers can select target strains much closer to the actual start of flu season, significantly reducing the risk of a mismatch.

First mRNA Flu Vaccine for Adults 50+ Now Available in Billings — Photo: health.yahoo.com

“It’s a huge thing for ensuring a healthy population, a healthy lifestyle, preventing, you know, pandemics,” said Kyle Austin, a Billings pharmacist.

Higher efficacy for aging immune systems

The decision to target adults 50 and older isn’t arbitrary. As people age, their immune systems typically don't respond as strongly to standard flu vaccines. The goal of mFlusiva was to create a more potent response for a demographic that is often more vulnerable to severe complications from the virus.

The data supports the approach. In a late-stage clinical trial involving more than 40,000 adults across 11 countries, mFlusiva was approximately 27 percent more effective than a standard-dose flu vaccine at preventing laboratory-confirmed influenza in adults 50 and older. While younger adults in earlier research showed even stronger immune responses, they also experienced more short-term side effects.

The safety profile remains consistent with existing vaccines. Clinical trials identified no new safety concerns, though common reactions include fatigue, headache, nausea, fever, and pain at the injection site.

First mRNA Flu Vaccine Now at Select Billings Pharmacies for Adults 50+

Availability lags behind approval

Despite the FDA’s August approval, the vaccine isn’t yet universal across all healthcare providers. In Billings, the shot is currently available at select pharmacies, including Albertsons and CVS. However, larger health systems like Intermountain Health, Riverstone Health, and Billings Clinic do not yet have the vaccine in stock.

This gap between regulatory approval and pharmacy availability creates a practical dilemma for patients. Dr. Neil Ku, an infectious disease specialist with Billings Clinic, warns that waiting for a specific brand of vaccine can be a dangerous gamble.

“Don’t hold out for one flu shot if it means putting off a flu shot altogether,” Dr. Ku advised.

The trade-off of a more potent response

While the increased efficacy is a win for public health, the “extra-potent” nature of the mRNA approach comes with a trade-off. The more aggressive the immune response, the more likely the patient is to feel the effects of the vaccine. The common reactions—chills, muscle pain, and joint pain—are essentially the body’s “training” session.

There is also the broader question of public trust. mRNA technology became a household term during the COVID-19 pandemic, and for some, that association brings skepticism.

As the 2026 flu season accelerates, the conversation in the doctor’s office is shifting. It is no longer just about whether a patient has been vaccinated, but which technology is powering their protection.